Clinical trials to examine CQ and its analogues as disease-modifying treatments against neurodegenerative diseases were mostly undertaken in Europe and Australia, where most participants would likely carry the stable C/C NQO1 genotype. This evidence concerns the gene NQO1 and neurodegenerative disease.